Rydapt
NICE says yes to Novartis’ Rydapt for rare blood disorder
Phil Taylor
HEOR, NICE, Novartis, rare disease, Rydapt, systemic mastocytosis
0 Comment
X
NICE says yes to Novartis’ Rydapt for rare blood disorder
https://pharmaphorum.com/news/nice-says-yes-to-novartis-rydapt-for-rare-blood-disorder/
Blueprint’s latest approval for Ayvakit sets up clash with Novartis
Phil Taylor
Ayvakit, Blueprint Medicines, FDA approval, Novartis, Oncology, Rydapt, systemic mastocytosis
0 Comment
X
Blueprint’s latest approval for Ayvakit sets up clash with Novartis
https://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/